Citations with the tag: LFB Biotechnologies SAS
Results 1 - 8
- Financings Roundup.
// BioWorld Today; 2/23/2010, Vol. 21 Issue 35, p8
The article reports on the seven million U.S. loan secured by GTC Biotherapeutics Inc. from LFB Biotechnologies.
- DSM Biologics and Crucell Enter Licensing Deal.
Bryner, Michelle // Chemical Week; 8/1/2007, Vol. 169 Issue 26, p19
The article reports that DSM Biologics and Crucell of Leiden, the Netherlands have entered into an agreement to license a manufacturing technology based on the companies' jointly developed PER.C6 cell line, to LFB Biotechnologies of Paris, France. LFB will use the licensed technology to develop...
- Collaborations: DSM Biologics and Crucell Announce Licensing Deal with LFB Biotechnologies.
Bryner, Michelle // Pharmaceutical Technology; Sep2007, Vol. 31 Issue 9, p134
The article reports that DSM Biologics of New Jersey and the biotechnology company Crucell NV of the Netherlands has signed a nonexclusive research licensing agreement with LFB Biotechnologies of Paris, France. It is stated that the LFB will use the PER.C6 production technology of Crucell to...
- Financings Roundup.
Bryner, Michelle // BioWorld Today; 11/3/2009, Vol. 20 Issue 212, p4
The article reports on the stock options exercised by LFB Biotechnologies, a strategic shareholder of GTC Biotherapeutics Inc., for the acquisition of the 12.8 million U.S. dollars of additional convertible preferred stock under the terms of a July 2009 financing agreement. Included in the deal...
- Lymphoma Update.
Bryner, Michelle // PharmaWatch: Cancer; Sep2007, Vol. 6 Issue 9, p4
The article offers information related to lymphoma update in Great Britain. Enzon Pharmaceuticals Inc. has started enrollment for its Phase I cancer drug trial. The GTC Biotherapeutics Inc. and LFB Biotechnologies have started development of a monoclonal antibody produced in the milk of...
- In Detail.
Bryner, Michelle // BioPharm International; Nov2006, Vol. 19 Issue 11, p18
The article offers news briefs related to biotechnology companies in the U.S. Amgen Inc. has acquired the Avida Group GmbH for $290 million. GTC Biotherapeutics Inc. and LFB Biotechnologies have entered into a strategic collaboration to make selected recombinant plasma proteins and monoclonal...
- Infectious Diseases News Round-Up.
Bryner, Michelle // PharmaWatch: Monthly Review; Feb2010, Vol. 9 Issue 2, p18
No abstract available.
- FINANCINGS ROUNDUP.
Bryner, Michelle // BioWorld Today; 6/22/2009, Vol. 20 Issue 118, p2
This sections offers news briefs on finance issues in the biotechnology industry. A shelf registration statement was filed by Abraxis BioScience Inc. to offer up to $400 million of its debt securities, common stock, preferred stock or warrants. Commitments were received by AEterna Zentaris Inc....